

Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222

Shu-Hsing Cheng^{1,2}, Yi-Chun Lin¹, Cheng-Pin Chen^{1,3}, *Chien-Yu Cheng^{1,4}

¹Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan

²School of Public Health, Taipei Medical University, Taipei, Taiwan

³Institute of Public Health, School of Medicine National Yang-Ming Chiao Tung University

⁴School of Clinical Medicine, National Yang-Ming Chiao Tung University, Taipei, Taiwan

*Corresponding author: s841060@gm.ym.edu.tw

Abstract

We report the interim safety and immunogenicity results in participants administered with a booster dose of protein subunit vaccine MVC-COV1901 at 12 or 24 weeks after two doses of AZD1222 (ChAdOx1 nCoV-19). In subjects fully vaccinated with two doses of AZD1222, waning antibody immunity was apparent within six months of the second dose of AZD1222. At one month after the MVC-COV1901 booster dose, anti-SARS-CoV-2 spike IgG antibody titers and neutralizing antibody titers were 14- and 8.6-fold increased, respectively, when compared to the titer levels on the day of the booster dose. These interim results support the use of MVC-COV1901 as a heterologous booster for individuals vaccinated with AZD1222.

Introduction

The COVID-19 pandemic is claiming millions of lives worldwide and the negative economic and public health impacts may have been far greater without the currently approved vaccines including the two mRNA- and two adenovirus-based anti-SARS-CoV-2 vaccines from Moderna or Pfizer/BioNTech and Oxford/AstraZeneca or Johnson & Johnson, respectively. These vaccines are highly efficacious in preventing serious disease, hospitalization and death and have demonstrated good safety records overall [1]. Nevertheless, as is the case with all vaccines, there are rare but severe safety signals that have led to limited applicability to specific patient subgroups. Examples are the mRNA vaccines that have been associated with rare events of myocarditis in younger males and thrombosis associated with adenoviral vector vaccines [2, 3].

New evidence shows challenges that comes with an increased infectiousness and immune evasion of emerging variants [4, 5] and the discovery of a relatively short duration of protection conferred by COVID-19 vaccines. These are concerns that developed with the resurgence of cases and the observation that vaccinated people show increasing rates of infection starting about 6 months post-vaccination [6]. Thus, consensus is building that long term COVID-19 control may be achieved by booster shots that may well become annual events [7].

AstraZeneca AZD1222 has the lowest cost amongst approved vaccines and because there is no need for an extreme-cold chain infrastructure such as the one needed for the mRNA vaccines, it is ideal for use in lower and middle-income countries [8, 9]. However,

AZD1222 has been found to be of weaker immunogenicity compared to other widely used mRNA vaccines, but boosters may compensate for this potential deficiency [10]. If proven, this may lead to a truly cost-effective vaccine-booster combination.

MVC-COV1901 is a subunit vaccine based on the stable prefusion spike protein (S-2P) of SARS-CoV-2 adjuvanted with CpG 1018 and aluminum hydroxide and has been approved for use after a large phase 2 clinical trial demonstrated favorable safety and immunogenicity profiles [11]. An EUA was granted to MVC-COV1901 since July, 2021 and the vaccine was rolled-out in Taiwan since the end of August, 2021. Based on a post-marketing safety surveillance system run by the Taiwanese Centers for Disease Control, no alarming safety signals have been reported for MVC-COV1901 [12]. Thus, we are investigating if MVC-COV1901 boosters can attain optimal immunogenicity after waning immunity from initial immunization(s).

In this study we report results from an MVC-COV1901 booster shot after two initial immunizations with AZD1222. We used data to quantify anti-SARS-CoV-2 spike IgG antibody titers and neutralizing antibody titers boosted by an MVC-COV1901 booster dose and describe the initial safety findings of the booster dose.

Methods

This study is a parallel, prospective, randomized, open-label, clinical study to evaluate the immunogenicity, safety, and tolerability of MVC-COV1901 as a booster vaccine in participants that have received two doses of AZD1222.

Two hundred and one healthy adults from age of 23 to 66 years that have received two doses of AZD1222 within 6 months of study initiation were randomized into two groups. Participants in Group A were scheduled to receive a booster dose of MVC-COV1901 (15 mcg of S2-P adjuvanted with 750 mcg of CpG 1018 and 375 mcg of aluminum hydroxide) administered intramuscularly 12 weeks after the last dose of AZD1222, whereas those in Group B were scheduled to receive a booster dose of MVC-COV1901 administered intramuscularly 24 weeks after the last dose of AZD1222. For analysis of the immunogenicity, 73 respondents were selected. The study design and flowchart is presented in Figure 1. The timeline of the study is as outlined in Figure 2. Day 1 is defined as the day that Group A participants received the dose of MVC-COV1901 booster. Therefore, in Group B participants, the MVC-COV1901 is administered on Day 85. Blood samples were taken at immunization and during additional study visits (Days 29, 85 and 169).

Immunogenicity was assessed by measuring anti-SARS-CoV-2 spike IgG antibody and live-SARS-CoV-2 neutralizing assay as previously performed [11]. The detection and characterization of antigen-specific immunoglobulin was performed by a central laboratory using a validated enzyme-linked immunosorbent assay (ELISA) method. An eCRF was used to record the actual date and time of sample collection. Unique sample identification was used to always maintain blinding at the laboratory and to allow for automated sample tracking and storage. On the other hand, the detection and characterization of neutralizing antibodies were performed by central laboratories using validated pseudovirus and/or live virus neutralization assays. To measure neutralising antibody titers, wildtype SARS-CoV-2, Taiwan CDC strain number 4 (hCoV-19/ Taiwan/4/2020; GISAID accession ID EPI_ISL_411927), was titrated and 50% tissue culture infective dose (TCID₅₀) was

calculated. Vero E6 cells were seeded in 96-well plates (at 1.2×10^6 cells per well) and incubated. The serum samples underwent a total of eight two-fold dilutions, starting from a 1:8 dilution to a final dilution of 1:1024. Diluted serum samples were then mixed with an equal volume of 100 TCID₅₀ per 50 μ L of virus. After incubating the serum-virus mixture at 37°C for 1 h, it was added to the wells containing Vero E6 cells. The cells were then incubated at 37°C in a 5% CO₂ incubator for 4–5 days. The neutralising titer (NT₅₀) was estimated as the reciprocal of the highest dilution capable of inhibiting 50% of the cytopathic effect. The NT₅₀ results were calculated with the Reed-Muench method.

Anti-spike IgG titers and neutralizing antibody titers were converted to the WHO Standardized Unit, BAU/mL and IU/mL, respectively. The conversion is based on the WHO validated NIBSC reference panel. Results are expressed as geometric mean titer (GMT) and converted to binding antibody units (BAU/mL) for IgG titer and international units (IU/mL) for neutralizing antibody titer as we have performed in our phase 2 clinical study [11]. Safety was assessed by monitoring for solicited and unsolicited adverse events (AEs) for the first 14 days after the booster dose, and 28 days and 12 weeks after the booster dose.

Results

In this interim report, we describe the findings from the Group A as Group B is still in progress at the time of writing. Table 1 summarizes the demographic characteristics of the sample. The median age of Group A is 40 years with an Interquartile range (IQR) of 13.0 years, while approximately 32% are males. In terms of Body Mass Index (BMI) approximately 13% in the group have BMI greater than 30 kg/m². Median BMI is 23.97 kg/m² with an IQR of 6.03. Figures 3 and 4 involved analyzing data from a subsample of 73 respondents.

The results of immunogenicity are summarized in Table 1 and Figure 3. Figure 3 shows the anti-spike IgG titers at T1: 28 days after the second AZD1222 shot; T2: day of vaccination for the MVC-COV1901 booster shot within three months after the last AZD1222 dose; and T3: one month after a booster dose of MVC-COV1901. At T1, the anti-spike IgG geometric mean was at 144.7 BAU/mL and the levels dropped to 52.1 BAU/mL at T2. At one month after the MVC-COV1901 booster dose (T3), anti-spike IgG levels increased to 724.9 BAU/mL or an almost 14-fold increase compared to on the day of booster dose (T2). Compared to T1, boosting by a third dose of MVC-COV1901 elicited a 5.0-fold increase in anti-spike IgG immune response. As shown in Table 3, the neutralizing antibody (NAb) titer was increased from 59.0 IU/mL at the time of booster dose to 385.4 IU/mL at one month after the MVC-COV1901 booster dose. This amounted to 6.5-fold increase of NAb levels at T3 compared to T2 in terms of IU/mL or a 8.6-fold increase in NT₅₀ (Table 3).

Injection of a third shot of MVC- COV1901 was generally safe and no adverse effects greater than mild (grade 1) to moderate (grade 2) were reported. No serious adverse event was reported after a booster shot with MVC-COV1901 in participants who had received two immunizations with AZD1222. Table 2 presents the safety profile of the third dose of MVC-COV1901. Among recipients of the MVC-COV1901 booster shot, approximately 72% experienced pain or tenderness at the site of injection within 14 days after the shot. A

noticeably lower proportion (i.e. 46%) of participants reported injection-site induration or swelling. Majority of those who encountered local solicited side effects, encountered grade 1 or mild effects while a small percentage experienced moderate reaction. In terms of systemic solicited AE, 51% experienced malaise or fatigue while none experienced fever. The most commonly reported systemic events were malaise or fatigue and myalgia (51% and 39%, respectively). Most systemic reactions reported were grade 1 with a few grade 2 reactions.

Discussion

The antibody quantifications presented here demonstrate that following a waning period post second immunization with AZD1222, a booster shot with MVC-COV19 significantly raises binding antibody level by as much as 14-fold. More importantly, maximum antibody levels achieved with the booster exceed the maximum levels achieved by two immunizations with AZD1222. Similar results have been observed in an extension of the MVC-COV1901 phase 1 trial that followed the same observation and vaccination time points as this study, but used MVC-COV1901 for all three immunizations [13, 14].

The aggregated results from the phase 1 study and the study presented here, suggest that options of a booster vaccine may not be limited to the matching vaccines for the primary series. More importantly, boosters may have the general property of efficiently raising neutralizing antibody to levels not achieved by prior immunizations [15, 16]. Based on the correlates of protection published from Phase III data of AZD1222, the predicted VE against symptomatic infection against the ancestral strain at four months after the second AZD1222 dose was below 60%, after the booster the predicted VE was raised to 89.7%. [17]. There is, however, an important follow up question that is to determine if the neutralizing antibody levels are better maintained long term after one or more boosters. The immunogenic response and favorable safety profile of the third booster shot might offer a viable option for vaccination program designers to cope with the issue of waning immunity after the two-dose schedule compounded by the emergence of variant of concerns.

Recent study in the UK for heterologous third dose booster regimen (COV-BOOST) showed that at one month after booster dose compared to the day of the booster dose, there was a 2.6-fold increase in anti-spike IgG titer with two doses plus a booster dose of AZD1222 and a 6.7-fold increase with two doses of AZD1222 and a booster dose of Novavax NVX-CoV2373, also a protein subunit vaccine [18]. In our study, a booster dose of MVC-COV1901 after two doses of AZD1222 showed a 14-fold increase in anti-spike IgG titer, superior to that of the above two combinations and nearly equal to that of boosting with BNT162b2 after two doses of AZD1222, which achieved a 16-fold increase in the COV-BOOST study [18]. In terms of reactogenicity, we have observed no occurrence of severe (grade 3) adverse events after booster administration, while severe solicited reactions have been reported for all of heterologous booster combinations in the COV-BOOST study [18]. Most noticeably, no incidence of fever has been reported in this study, similar to our previous clinical findings [11].

From our interim findings, we showed that administration of MVC-COV1901 as a third dose booster could effectively and safely enhance immunogenicity nearly to the level as seen in using mRNA vaccine as booster dose. Our strategy could be aptly applied to lower

and middle income countries that would have difficulties in handling mRNA booster vaccines but desirable to achieve a similarly high level of immunity against SARS-CoV-2.

Conflict of Interest Disclosure:

The authors declare no conflict of interest.

Funding/Support:

Medigen Vaccine Biologics Corporation and Taiwan Centers for Disease Control, Ministry of Health and Welfare.

Author Contributions:

Concept and design: S.-H.C.

Acquisition and interpretation/analysis of data, manuscript preparation: S.-H.C., Y.-C.L., C.-P.C., and C.-Y. C.

Additional Contributions:

The Institute of Biomedical Sciences, Academia Sinica performed the neutralization assay. Members of Medigen Vaccine Biologics Corp. assisted in manuscript editing and revision.

Ethics Statement:

The trial protocol and informed consent form were approved by the Medical Ethics and Institutional Review Board of Taoyuan General Hospital. The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. This trial is registered on ClinicalTrials.gov: NCT05097053.




Figure 1. Study design and flowchart




Figure 2. Study timeline and key time points.




Figure 3. Anti-SARS-CoV-2 spike IgG titers at different time points. Results were presented by A) blue line/dot for each individual IgG level and B) bars representing geometric mean IgG titer with error bars for 95% confidence interval values.

T1: 28 days after second dose of AZD1222; T2: On the day of MVC-COV1901 booster dose; T3: 28 days after MVC-COV1901 booster dose

Table 1. Demographic profile of respondents

Item\MVC lot	Vaccine group		p-value
	Group A	Group B	
<input type="checkbox"/> Age (years)			
N (Missing)	100 (0)	101 (0)	
Mean (SD)	41.4(10.3)	42.03 (10.9)	
Median (IQR)	40 (13.0)	40 (16.0)	0.673
Q1~Q3	34.5~47.5	35~51	
Min~Max	24~66	23~66	
<input type="checkbox"/> Gender			
N (Missing)	100 (0)	101 (0)	
Male	32 (32.0)	29 (28.7)	0.612
Female	68 (68.0)	72 (71.3)	

□ BMI (kg/m²)			
N (Missing)	100(0)	101(0)	
Mean (SD)	24.4(4.4)	24.6 (4.2)	
Median (IQR)	23.97(6.03)	23.8 (6.3)	0.74
Q1~Q3	21.2~27.2	21.3~27.6	
Min~Max	17.6~35.3	17.99~37.8	
□ BMI group			
N (Missing)	100 (0)	101 (0)	
<30 kg/m ²	87 (87.0)	88 (87.1)	0.978
>=30 kg/m ²	13 (13.0)	13 (12.9)	
□ Comorbidity Category			
N (Missing)	100 (0)	101 (0)	
Yes	32 (32.0)	25 (24.8)	0.254
No	68 (68.0)	76 (75.3)	

(1) Abbreviations: N=number of subjects in PPI population; SD=standard deviation; Q1=first quartile (25th percentile); Q3=third quartile (75th percentile); IQR=interquartile range; BMI=Body Mass Index; HIV=Human Immunodeficiency Virus.

Table 2. Solicited Adverse Effects 14 days after an MVC-COV1901 booster shot

	Event	Participant n (%)
N (missing)		100 (0)
At least one event	257	82
Local	120	74(74.0)
Pain/Tenderness	72	72(72.0)
Grade 1	71	71(71.0)
Grade 2	1	1(1.0)
Grade 3	0	0(0)
Erythema/Redness	2	2(2.0)
Grade 1	2	2(2.0)
Grade 2	0	0(0)
Grade 3	0	0(0)
Induration/Swelling	46	46(46.0)
Grade 1	46	46(46.0)
Grade 2	0	0(0)
Grade 3	0	0(0)
Systemic	137	63(63.0)
Malaise/Fatigue	51	51(51.0)
Grade 1	48	48(48.0)
Grade 2	3	3(3.0)

Grade 3	0	0(0)
Myalgia	39	39(39.0)
Grade 1	35	35(35.0)
Grade 2	4	4(4.0)
Grade 3	0	0(0)
Headache	30	30(30.0)
Grade 1	29	29(29.0)
Grade 2	1	1(1)
Grade 3	0	0(0)
Diarrhea	7	7(7.0)
Grade 1	7	7(7.0)
Grade 2	0	0(0)
Grade 3	0	0(0)
Nausea/Vomiting	10	10(10.0)
Grade 1	10	10(10.0)
Grade 2	0	0(0)
Grade 3	0	0(0)
Fever	0	0(0)
Grade 1	0	0(0)
Grade 2	0	0(0)
Grade 3	0	0(0)

Table 3. Immunogenicity at T2 (day of MVC-COV1901 booster) and T3 (one month after MVC-COV1901 booster) as measured by anti-SARS-CoV-2 spike IgG titers and live virus neutralizing antibody titers. GMTs are shown as GMT with 95% confidence interval in the parentheses. Fold changes are calculated as geometric mean of the T3/T2 ratio of individual titer values with 95% confidence interval in the parentheses.


	Unit	T2	T3	Fold change T3/T2
Anti-SARS-CoV-2 spike IgG	IgG GMT	571.4 (456.6-715.1)	7948.7 (6558.5-9633.6)	13.9 (10.5-18.4)
	BAU/mL GMT	52.1 (41.6-65.2)	724.9 (598.1-878.6)	13.9 (10.5-18.4)
Neutralizing antibody	NT ₅₀ GMT	66.6 (56.6-78.4)	569.7 (471.7-688.0)	8.6 (7.0-10.5)
	IU/mL GMT	59.0 (51.2)	385.4 (326.8-454.5)	6.5 (5.5-7.8)

References


1. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. *Morbidity and Mortality Weekly Report*. 2021 Sep 24;70(38):1337.

2. US Centers for Disease Control and Prevention. Myocarditis and Pericarditis After mRNA COVID-19 Vaccination. Nov. 12, 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>. Accessed Nov. 29, 2021.
3. Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, McCowan C, Agrawal U, Shah SA, Ritchie LD, Murray J. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nature Medicine*. 2021 Jun 9:1-8.
4. UK, G. (2020). Investigation of SARS-CoV-2 variants of concern: technical briefings.
5. Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., ... & Bauer, D. L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. *The Lancet*, 397(10292), 2331-2333.
6. Klompas M. Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination. *Jama*. 2021.
7. Sagonowsky E. “Moderna, citing variants and waning immunity, expects COVID-19 boosters to become a fact of life”. Aug 5, 2021. Available at: <https://www.fiercepharma.com/pharma/moderna-citing-variants-and-waning-immunity-expects-covid-19-boosters-to-become-a-fact-life>. Accessed 17 September, 2021.
8. The Guardian. Kolllewe, J. (2021) Covid-19 vaccines: the contracts, prices and profits. Available at <https://www.theguardian.com/world/2021/aug/11/covid-19-vaccines-the-contracts-prices-and-profits> . Accessed 06 Dec. 2021
9. BBC News. “Covid: What do we know about China's coronavirus vaccines?” Jan. 14, 2021. Available at: <https://www.bbc.com/news/world-asia-china-55212787>. Accessed Nov. 28, 2021.
10. Munro, APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet*. 2021 Dec.
11. Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC, Lee YL, Lin YL. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. *The Lancet Respiratory Medicine*. 2021 Oct 13.
12. Taiwan Centers for Disease Control. V-Watch Bulletin Report, Nov. 21, 2021. Available at: https://www.cdc.gov.tw/File/Get/Xwv8akaYldqmvLSsN3_H5Q. Accessed Nov. 29, 2021
13. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine*. 2021 May 17:1-7.
14. Hsieh, S., Chang, S, Cheng, H, Shih, S, Lien, C. The reactogenicity and immunogenicity of a booster dose after the second dose of a protein subunit vaccine MVC-COV1901. *MedRxiv*. (2021) Accessed at <https://doi.org/10.1101/2021.12.01.21267115> [preprint]
15. Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, Nunna N, Huang W, Oestreicher J, Colpitts T, Bennett H. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nature medicine*. 2021 Sep 15:1-7.
16. Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCov-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *The Lancet*. 2021 Sep 11;398(10304):981-90.

17. Feng, S., Phillips, D.J., White, T. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* 27, 2032–2040 (2021).
<https://doi.org/10.1038/s41591-021-01540-1>
18. Munro AP, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet*. 2021 Dec 2.



Group A




Vaccination



Immunogenicity Blood Sampling

Group B




Vaccination



Immunogenicity Blood Sampling

Interim Analysis

A.**B.**